Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04369612

Home Based Monitoring of Kidney Transplants Utilizing Capillary Microsamples — HBM-KTx  

Kidney Transplant Failure and Rejection Clinical Trial

Official title:
Home Based Monitoring of Kidney Transplants Utilizing Capillary Microsamples

Clinical Trial Summary

Renal transplant recipients are followed as out patients at the transplant center for about 8 weeks after surgery. Between 1-2 weeks after surgery, 50 standard immunological patients will be randomized (1:1) to either follow standard of care (SOC) or having every second poli clinical visit without entering the hospital HBM; Home Based Monitoring). They are to take a capillary finger-prick blood sample themselves, send it to the laboratory for analysis and then they will get a telecom follow-up that day from their transplant physician. Outcome is no difference with regards to being able to follow the randomized follow-up procedure.

Clinical Trial Description

Renal transplant recipients are followed as out patients at the transplant center for about 8 weeks after surgery. Between 1-2 weeks after surgery, 50 standard immunological patients (i.e. first, kidney (only) transplants, no donors specific antibodies (DSA), panel reactive antibodies (PRA), ABO blood type compatible transplant) will be randomized (1:1) to either follow standard of care (SOC) or having every second poli clinical visit without entering the hospital HBM; Home Based Monitoring). They are to take a capillary finger-prick blood sample themselves and send it to the laboratory for analysis (creatinine, hemoglobin, tacrolimus and mycophenolate) and then they will get a telecom follow-up that day from their transplant physician. Outcome is no difference with regards to being able to follow the randomized follow-up procedure without having acute rejection episodes and no need for extra ou-patients visits for any reason. End of study is week 7-8 after transplantation. ;

Study Design

Related Conditions & MeSH terms

  • Kidney Transplant Failure and Rejection
Clinical Trial Details
NCT number NCT04369612
Study type Interventional
Source Oslo University Hospital
Contact Karsten Midtvedt, MD, PhD
Phone 0047-23071894
Email kmidtved@ous-hf.no
Status Recruiting
Phase N/A
Start date April 28, 2020
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04057742 - AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
Recruiting NCT03465397 - Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients Phase 4
Completed NCT03437577 - Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients Phase 1/Phase 2
Not yet recruiting NCT05282966 - Assessment of QSant™ for Underlying Allograft Rejection
Recruiting NCT04388930 - The Microbiota in Kidney Donation and Transplantation
Completed NCT03611621 - A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
Recruiting NCT05397821 - Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
Completed NCT04019353 - Cf-DNA Assay During Treatment of Acute Rejection
Active, not recruiting NCT05806749 - Immunological Tolerance in Patients With Mismatched Kidney Transplants Phase 1
Recruiting NCT04936282 - Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING) Phase 4
Enrolling by invitation NCT05285878 - Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Phase 2
Recruiting NCT04526431 - Tacrolimus Pharmacokinetic Subpopulations
Active, not recruiting NCT03511560 - Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation Phase 4
Recruiting NCT03438773 - Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients Phase 1
Completed NCT05388955 - Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
Completed NCT06394596 - Predicting Prognostic Factors in Kidney Transplantation Using A Machine Learning
Completed NCT04413916 - MiRNA in Kidney Transplantation: Association With Kidney Graft Function and Disease Process
Completed NCT03466775 - Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes N/A
Active, not recruiting NCT04733131 - Long-term Outcomes After Conversion to Belatacept
Active, not recruiting NCT03380962 - Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Phase 1/Phase 2